Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.45 |
| ▸ | LPL | P06858 | 11/20 | 0.45 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23816604 | 1.00 | DGAT1 (0.45) | DGAT1LIPGLPLF11FFAR1 | |
| SCHEMBL28564928 | 0.91 | DGAT1 (0.43) | DGAT1LIPGLPLF11FFAR1 | |
| SCHEMBL2316680 | 0.87 | DGAT1 (0.47) | DGAT1LIPGLPLF11FFAR1 | |
| SCHEMBL2426973 | 0.82 | LPL (0.49) | DGAT1LIPGLPLF11FFAR1 | |
| SCHEMBL29744209 | 0.82 | LPL (0.49) | DGAT1LIPGLPLF11FFAR1 | |
| SCHEMBL2585735 | 0.82 | DGAT1 (0.46) | DGAT1LIPGLPLF11FFAR1 | |
| SCHEMBL31469579 | 0.81 | LPL (0.45) | DGAT1LIPGLPLF11FFAR1 | |
| SCHEMBL28769722 | 0.81 | DGAT1 (0.44) | DGAT1LIPGLPLF11FFAR1 | |
| SCHEMBL2428561 | 0.81 | LPL (0.45) | DGAT1LIPGLPLF11FFAR1 | |
| SCHEMBL3803828 | 0.81 | DGAT1 (0.44) | DGAT1LIPGLPLF11FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115335376-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitor with E3 ligase ligand and methods of use thereof | 百济神州有限公司 | 2022-11-11 | — | — | CN | disclosed |